AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8151001
Drug: Adinazolam mesylate
RxNorm normalized name: mesylate
DrugBank: Adinazolam (DB00546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam mesylate sustained release tablets, dosages titrated from 30 mg/day up to a maximum of 120 mg/day.
Trial: 8751014
Drug: Ketoprofen 150
RxNorm normalized name: ketoprofen 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 150 mg
Trial: 29576114
Drug: Goal-directed haemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed haemodynamic therapy (GDHT) using oesophageal Doppler monitor, aimed to maintain stroke volume, mean arterial pressure >70 mm Hg, and cardiac index ≥2.5 litres min‐1 m‐2
Trial: 29576114
Drug: Goal-directed haemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed haemodynamic therapy (GDHT)
Trial: 25588353
Drug: Levodopa-carbidopa intestinal
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-carbidopa intestinal gel (LCIG) in LCIG-naïve patients (N = 29)
Trial: 25588353
Drug: Levodopa-carbidopa intestinal
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-carbidopa intestinal gel (LCIG) in continuing-LCIG patients (N = 33)
Trial: 20185731
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (CSII)
Trial: 18232724
Drug: Levetiracetam (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (maximum dose of 3000 mg/day)
Trial: 10762579
Drug: Inhaled zanamivir
RxNorm normalized name: zanamivir Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled zanamivir (10 mg twice daily for 5 days)
Trial: 8103820
Drug: Monoclonal-antibody-purified FVIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal-antibody-purified FVIII concentrates
Trial: 27412789
Drug: D2-receptor antagonist
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2-receptor antagonist haloperidol
Trial: 25941810
Drug: 2 calcium-fortified
RxNorm normalized name: calcium(2+) chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 calcium-fortified cereal bars daily (total of 400 mg calcium/day)
Trial: 25941810
Drug: 2 calcium-fortified
RxNorm normalized name: calcium(2+) chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 calcium-fortified cereal bars daily
Trial: 17559359
Drug: Lansoprazole, bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, bismuth subcitrate, metronidazole, and amoxicillin (LBMA)
Trial: 17559359
Drug: Lansoprazole, bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, bismuth subcitrate, tetracycline, and amoxicillin (LBTA)
Trial: 17128840
Drug: 5% dexpanthenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dexpanthenol and zinc oxide ointment
Trial: 14618470
Drug: 20-mg oestradiol
RxNorm normalized name: estradiol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg oestradiol implants, replaced every 4 months
Trial: 11069229
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) daily for 3 months, followed by IFN 3 times weekly (TIW) for 12 months (group A)
Trial: 11069229
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) 3 times weekly (TIW) for 18 months (group B)
Trial: 1439406
Drug: Test compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test compound
Trial: 3969937
Drug: Zinc intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc intake of 18.5 mg/day for two consecutive weeks
Trial: 3969937
Drug: Zinc intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc intake of 3.5 mg/day above the RDA for men
Trial: 31450870
Drug: Endometrial scratching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial scratching with long agonist protocol
Trial: 31450870
Drug: Endometrial scratching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial scratching with antagonist protocol
Trial: 31450870
Drug: Stimulation with
RxNorm normalized name: INM-005 (PURIFIED FAB'2 FRACTION OF EQUINE HYPERIMMUNE SERUM GENERATED FROM ANTIGENIC STIMULATION WITH THE SARS-COV2 RBD PROTEIN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation with long agonist protocol
Trial: 31450870
Drug: Stimulation with
RxNorm normalized name: INM-005 (PURIFIED FAB'2 FRACTION OF EQUINE HYPERIMMUNE SERUM GENERATED FROM ANTIGENIC STIMULATION WITH THE SARS-COV2 RBD PROTEIN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation with antagonist protocol
Trial: 29384859
Drug: Comprehensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive periodontal treatment
Trial: 26519996
Drug: Higher beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher beta-blocker dose
Trial: 10325501
Drug: 4-HPR (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-HPR (two 100-mg capsules daily for 3 weeks)
Trial: 10325501
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules daily for 3 weeks)
Trial: 8519723
Drug: Intravenous phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phentolamine infusion (i.v.P) at 35 mg
Trial: 8519723
Drug: Intravenous phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phentolamine infusion (i.v.P) at higher doses (50 mg or 75 mg)
Trial: 6320943
Drug: Low-dose corticotrophin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticotrophin
Trial: 20522594
Drug: TUDCA (1,750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TUDCA (1,750 mg/day)
Trial: 15642073
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR 1000 mg once daily
Trial: 15642073
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR 500 mg once daily
Trial: 15642073
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR 1500 mg once daily
Trial: 15642073
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR 1000 mg twice daily
Trial: 29227571
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR
Trial: 10082501
Drug: Instant coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant coffee (5 cups per day, equivalent to 300 mg caffeine per day)
Trial: 2202240
Drug: Antacid (Mylanta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (Mylanta II)
Trial: 2202240
Drug: GI cocktail
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GI cocktail (antacid + 15 mL of 2% viscous lidocaine)
Trial: 7156248
Drug: L-tryptophan-amitriptyline combination
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan-amitriptyline combination
Trial: 27129009
Drug: ASP2151 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP2151 (100, 200, or 400 mg daily for 3 days)
Trial: 27129009
Drug: ASP2151 (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP2151 (1,200 mg as a single dose)
Trial: 17179772
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal single-dose cream (CVSDC)
Trial: 17179772
Drug: Metronidazole vaginal
RxNorm normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal gel (MVG)
Trial: 12428241
Drug: High-Dose D-Penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose D-Penicillamine
Trial: 12428241
Drug: Low-Dose D-Penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dose D-Penicillamine
Trial: 2492170
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine solution (0.8 mg/kg)
Trial: 31085282
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb treatment based on voluntary task‐oriented movements
Trial: 28295516
Drug: 5% BPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% BPO gel
Trial: 26268495
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy combined with metoprolol
Trial: 8320728
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) administered via infusion over 2 hours, with a total escalating dose from 18.0 to 33.5 mg.
Trial: 8320728
Drug: Vehicle placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle placebo administered via infusion over 2 hours.
Trial: 31173921
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy informed by Acceptance and Commitment Therapy (PACT)
Trial: 30326045
Drug: hu3F8 (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu3F8 (humanized anti-GD2 antibody) infused intravenously for 30 minutes on Monday, Wednesday, and Friday, with dosage escalation up to 9.6 mg/kg/cycle (approximately 288 mg/m2)
Trial: 30326045
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor administered subcutaneously daily from 5 days before infusion through the last day of infusion
Trial: 30326045
Drug: Higher dosing
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosing of hu3F8
Trial: 18936215
Drug: Cysteine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine intake of 10 mg x kg(‐1) x d(‐1)
Trial: 18936215
Drug: Cysteine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine intake of 20 mg x kg(‐1) x d(‐1)
Trial: 18936215
Drug: Cysteine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine intake of 30 mg x kg(‐1) x d(‐1)
Trial: 18936215
Drug: Cysteine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine intake of 40 mg x kg(‐1) x d(‐1)
Trial: 18936215
Drug: Cysteine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine intake of 0 mg x kg(‐1) x d(‐1)
Trial: 12578880
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with enalapril or nisoldipine; mean blood pressure of 128/75 mm Hg over 4 years.
Trial: 2071809
Drug: Phenylpropanolamine hydrochloride
RxNorm normalized name: Phenylpropanolamine Hydrochloride
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine hydrochloride (50 mg a day, increasing to 50 mg twice a day)
Trial: 21161222
Drug: Fluid plus
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid plus vasopressin (4 IU bolus and 2.4 IU/h infusion for 5 hours)
Trial: 18693827
Drug: Wireless devices
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless devices (PDAs and tablet PCs)
Trial: 12042191
Drug: Divalproex (500-2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex (500-2500 mg/day in divided doses)
Trial: 9676304
Drug: Electrolyte solution
RxNorm normalized name: electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte solution (VE)
Trial: 2193836
Drug: Cefetamet 500
RxNorm normalized name: cefetamet 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet 500 mg orally twice daily for 7 days
Trial: 2193836
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg orally three times daily for 7 days
Trial: 25789444
Drug: Water only
RxNorm normalized name: Water only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water only (treatment A)
Trial: 25789444
Drug: Water +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water + cola (treatment B)
Trial: 25789444
Drug: Water +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water + diet cola (treatment C)
Trial: 25789444
Drug: Water +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water + cola + diet cola + orange juice (treatment D)
Trial: 21332346
Drug: Low-dose NCTD
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose NCTD (0.05 mg/kg/day)
Trial: 21332346
Drug: High-dose NCTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose NCTD (0.1 mg/kg/day)
Trial: 21332346
Drug: Model group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model group (DN rats without treatment)
Trial: 19732995
Drug: Placebo-control group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-control group (with weekly relaxation sessions)
Trial: 15497493
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated estrogen (CE)/5 mg medroxyprogesterone acetate (MPA)
Trial: 15497493
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol/1 mg norethisterone acetate (NETA)
Trial: 11521964
Drug: CLA supplementation
RxNorm normalized name: CLA
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLA supplementation (Tonalin capsules providing 3.9 g/d of CLA isomers)
Trial: 11521964
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil (sunflower) supplementation (6 daily capsules of 1 g each)
Trial: 7921857
Drug: Esmolol 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 60 mg
Trial: 7921857
Drug: Esmolol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 40 mg
Trial: 7921857
Drug: Esmolol 20
RxNorm normalized name: esmolol 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 20 mg
Trial: 3377947
Drug: Extradural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural diamorphine 5 mg in saline 10 ml with adrenaline 1 in 200,000
Trial: 3377947
Drug: Extradural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural diamorphine 5 mg in saline 10 ml without adrenaline (saline group)
Trial: 31297513
Drug: Self-assessment using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-assessment using a tablet
Trial: 31297513
Drug: Self-assessment using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-assessment using a tablet (for patients aged ≥85)
Trial: 31297513
Drug: Self-assessment using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-assessment using a tablet (for caregivers)
Trial: 1420749
Drug: Algicon Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algicon Suspension
Trial: 6319067
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg every 12 hr)
Trial: 21907450
Drug: Curcuminoids (6000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (6000 mg/d in 3 divided doses)
Trial: 18184542
Drug: Huannao Yicong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huannao Yicong capsule
Trial: 11530030
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled fluticasone (88 microg twice daily)
Trial: 11530030
Drug: Oral zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral zafirlukast (20 mg twice daily)
Trial: 11530030
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from zafirlukast to fluticasone (88 microg twice daily)
Trial: 7930305
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg three times daily)
Trial: 31980978
Drug: Benzbromarone 50
RxNorm normalized name: benzbromarone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzbromarone 50 mg
Trial: 30219400
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol before primary PCI
Trial: 25987198
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for panic disorder
Trial: 21486113
Drug: Long-term anticoagulation
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term anticoagulation therapy with warfarin (OAC group)
Trial: 21486113
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anticoagulant or antiaggregant drugs)
Trial: 11789221
Drug: Composite Salviae
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Salviae Dropping Pill (CSDP), 10 pills three times a day for 4 weeks
Trial: 11789221
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (aspirin and other conservative agents only)
Trial: 9095007
Drug: Albuterol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2.5 mg) every 60 minutes for two doses, interspersed with saline aerosols every 20 minutes
Trial: 9095007
Drug: Albuterol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2.5 mg) every 20 minutes for 2 hours
Trial: 8459640
Drug: Primary gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary gastric lesion responded to chemotherapy
Trial: 8459640
Drug: Primary gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary gastric lesion did not respond to chemotherapy
Trial: 28303753
Drug: FTC/TAF (unboosted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TAF (unboosted third agent)
Trial: 28303753
Drug: FTC/TDF (unboosted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TDF (unboosted third agent)
Trial: 22562974
Drug: MR prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR prednisone 5 mg once daily in the evening plus DMARD
Trial: 6373441
Drug: Dipyrone 500
RxNorm normalized name: dipyrone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 500 mg
Trial: 21457066
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (LIS)
Trial: 23038415
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% levobupivacaine with 5 μg/mL epinephrine
Trial: 23038415
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% levobupivacaine without epinephrine
Trial: 16005438
Drug: Metyrapone (cortisol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (cortisol synthesis inhibitor)
Trial: 14564242
Drug: Vecuronium (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (1.3 mg/kg)
Trial: 1832944
Drug: TAM (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM (20 mg b.i.d.)
Trial: 1832944
Drug: TAM-MPA (TAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM-MPA (TAM 20 mg b.i.d. for 7 days, then TAM plus 500 mg MPA for 7 days)
Trial: 3545685
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g per day)
Trial: 19021097
Drug: Feeding in
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeding in anemic infants > 1250 g
Trial: 17936446
Drug: Live-attenuated influenza
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated influenza vaccine, trivalent
Trial: 11985880
Drug: Creatine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (8 g/day for 5 days)
Trial: 10397695
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin (r‐hirudin) 0.35 mg/kg
Trial: 8749149
Drug: Loratadine 40
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine 40 mg daily
Trial: 6282302
Drug: Medium-fibre coarse-bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-fibre coarse-bran bread diet (22 g NDF/d)
Trial: 6282302
Drug: High-fibre coarse-bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fibre coarse-bran bread diet (35 g NDF/d)